MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

We analysed the prognostic significance of minimal residual disease (MRD) level in adult patients with acute myeloid leukemia (AML) treated in the randomized gemtuzumab ozogamicin (GO) ALFA-0701 trial. Levels of WT1 and NPM1 gene transcripts were assessed using cDNA-based real-time quantitative PCR...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lambert, Juliette, Lambert, Jérôme, Nibourel, Olivier, Pautas, Cécile, Hayette, Sandrine, Cayuela, Jean-Michel, Terré, Christine, Rousselot, Philippe, Dombret, Hervé, Chevret, Sylvie, Preudhomme, Claude, Castaigne, Sylvie, Renneville, Aline
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2014
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171629/
https://ncbi.nlm.nih.gov/pubmed/25026287
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi